These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3740659)

  • 21. Vasodilator therapy for primary pulmonary hypertension.
    McGoon MD; Vlietstra RE
    Mayo Clin Proc; 1984 Oct; 59(10):672-7. PubMed ID: 6148467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Persistent hemodynamic and clinical improvement after captopril in patients with pulmonary hypertension.
    Stumpe KO; Schmengler K; Bette L; Overlack A; Kolloch R
    Herz; 1986 Aug; 11(4):217-25. PubMed ID: 3093346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute and long-term effects of inhaled iloprost in portopulmonary hypertension.
    Melgosa MT; Ricci GL; García-Pagan JC; Blanco I; Escribano P; Abraldes JG; Roca J; Bosch J; Barberà JA
    Liver Transpl; 2010 Mar; 16(3):348-56. PubMed ID: 20209595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of the calcium antagonist nifedipine on central and peripheral hemodynamics in patients with primary pulmonary hypertension].
    Khosseĭn A; Mareev VIu; Ageev FT; Sazonova LN; Lobova NM
    Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR; 1988; 11(1):78-81. PubMed ID: 3401345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.
    McLaughlin VV; Genthner DE; Panella MM; Rich S
    N Engl J Med; 1998 Jan; 338(5):273-7. PubMed ID: 9445406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vasodilator therapy for primary pulmonary hypertension. Limitations and hazards.
    Packer M
    Ann Intern Med; 1985 Aug; 103(2):258-70. PubMed ID: 2861770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension.
    Rich S; Brundage BH; Levy PS
    Circulation; 1985 Jun; 71(6):1191-6. PubMed ID: 3995712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nesiritide acutely increases pulmonary and systemic levels of nitric oxide in patients with pulmonary hypertension.
    Khush KK; De Marco T; Vakharia KT; Harmon C; Fineman JR; Chatterjee K; Michaels AD
    J Card Fail; 2006 Sep; 12(7):507-13. PubMed ID: 16952783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension.
    Weir EK; Rubin LJ; Ayres SM; Bergofsky EH; Brundage BH; Detre KM; Elliott CG; Fishman AP; Goldring RM; Groves BM
    Am Rev Respir Dis; 1989 Dec; 140(6):1623-30. PubMed ID: 2690706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacology of the pulmonary circulation].
    Follath F
    Schweiz Med Wochenschr; 1985 Sep; 115(39):1328-32. PubMed ID: 2866581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sildenafil improves dynamic vascular function in the brain: studies in patients with pulmonary hypertension.
    Rosengarten B; Schermuly RT; Voswinckel R; Kohstall MG; Olschewski H; Weissmann N; Seeger W; Kaps M; Grimminger F; Ghofrani HA
    Cerebrovasc Dis; 2006; 21(3):194-200. PubMed ID: 16388195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Vasodilator agents in pulmonary artery hypertension of systemic scleroderma].
    Phlippoteau C; Brenot F; Blétry O; Simmonneau G; Duroux P
    Rev Mal Respir; 1990; 7(3):249-54. PubMed ID: 2114030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hope in primary pulmonary hypertension.
    Reeves JT
    N Engl J Med; 1980 Jan; 302(2):112-3. PubMed ID: 7350416
    [No Abstract]   [Full Text] [Related]  

  • 34. Deleterious effects of hydralazine in patients with pulmonary hypertension.
    Packer M; Greenberg B; Massie B; Dash H
    N Engl J Med; 1982 Jun; 306(22):1326-31. PubMed ID: 7070457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effects of pimobendan on pulmonary hypertension in patients with chronic pulmonary emphysema].
    Yamazaki Y; Matsumoto H; Takeda A; Takahashi T; Sasaki N; Takahashi M; Tsuji T; Fujikane T; Shimizu T
    Nihon Kyobu Shikkan Gakkai Zasshi; 1997 Aug; 35(8):847-53. PubMed ID: 9366158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hemodynamic effects of urapidil in patients with pulmonary hypertension. A comparative study with hydralazine.
    Adnot S; Defouilloy C; Brun-Buisson C; Abrouk F; Piquet J; Lemaire F
    Am Rev Respir Dis; 1987 Feb; 135(2):288-93. PubMed ID: 3813189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vasodilator therapy after heart transplantation: effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin E1, and sodium nitroprusside.
    Kieler-Jensen N; Lundin S; Ricksten SE
    J Heart Lung Transplant; 1995; 14(3):436-43. PubMed ID: 7654728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Noninvasive assessment of hemodynamic improvement during chronic vasodilator therapy in obliterative pulmonary hypertension.
    D'Alonzo GE; Gianotti L; Dantzker DR
    Am Rev Respir Dis; 1986 Mar; 133(3):380-4. PubMed ID: 3954246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sildenafil for primary and secondary pulmonary hypertension.
    Watanabe H; Ohashi K; Takeuchi K; Yamashita K; Yokoyama T; Tran QK; Satoh H; Terada H; Ohashi H; Hayashi H
    Clin Pharmacol Ther; 2002 May; 71(5):398-402. PubMed ID: 12011826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vasodilator therapy for pulmonary hypertensive disorders.
    Hyman AL; Kadowitz PJ
    Chest; 1984 Feb; 85(2):145-7. PubMed ID: 6692692
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.